Get the Stockscreener App
1.26
5.97%
-0.08
Pre-market:
1.27
0.01
+0.79%
Mira Pharmaceuticals Inc stock is traded at $1.26, with a volume of 317.32K.
It is down -5.97% in the last 24 hours and down -17.11% over the past month.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
See More
Previous Close:
$1.34
Open:
$1.35
24h Volume:
317.32K
Relative Volume:
0.38
Market Cap:
$24.03M
Revenue:
-
Net Income/Loss:
$-11.24M
P/E Ratio:
-1.6546
EPS:
-0.7615
Net Cash Flow:
$-4.79M
1W Performance:
-6.67%
1M Performance:
-17.11%
6M Performance:
+49.36%
1Y Performance:
+16.67%
1-Day Range:
$1.25
$1.35
1-Week Range:
$1.25
$1.37
52-Week Range:
$0.73
$2.56
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Name
Mira Pharmaceuticals Inc
Sector
Industry
Phone
813-369-5150
Address
1200 BRICKELL AVENUE, MIAMI
Compare MIRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
1.26 | 25.55M | 0 | -11.24M | -4.79M | -0.7615 |
|
LLY
Lilly Eli Co
|
833.49 | 766.78B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
190.72 | 460.19B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
230.50 | 407.53B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
130.03 | 253.71B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
85.99 | 218.56B | 63.43B | 16.42B | 14.72B | 6.4861 |
Mira Pharmaceuticals Inc Stock (MIRA) Latest News
Price momentum metrics for MIRA Pharmaceuticals Inc. explainedTake Profit & Weekly Breakout Watchlists - newser.com
Can MIRA Pharmaceuticals Inc. stock surprise with earnings upsideFed Meeting & High Accuracy Swing Entry Alerts - newser.com
MIRA Pharmaceuticals reports positive in vitro drug release data for topical Ketamir-2 - MSN
MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog - Livingston Daily
What drives MIRA Pharmaceuticals Inc stock priceStock Price Targets & Budget Investment Success - earlytimes.in
Is MIRA Pharmaceuticals Inc. stock a buy in volatile marketsMarket Sentiment Report & Technical Pattern Alert System - newser.com
MIRA Pharmaceuticals Inc. stock daily chart insightsPortfolio Profit Report & Precise Swing Trade Alerts - newser.com
What machine learning models say about MIRA Pharmaceuticals Inc.Weekly Risk Summary & Proven Capital Preservation Tips - newser.com
MIRA Pharmaceuticals Inc Stock Analysis and ForecastTechnical Resistance Breaks & Free Hedging Tactics for Volatile Markets - earlytimes.in
Published on: 2025-10-09 04:14:21 - newser.com
Is MIRA Pharmaceuticals Inc. reversing from oversold territory2025 EndofYear Setup & Precise Swing Trade Alerts - newser.com
Trend analysis for MIRA Pharmaceuticals Inc. this weekMarket Activity Recap & Daily Volume Surge Signals - newser.com
What analysts say about MIRA Pharmaceuticals Inc stockEquity Performance Review & Low Cost Trading Plans - earlytimes.in
What indicators show strength in MIRA Pharmaceuticals Inc.Market Performance Recap & AI Optimized Trading Strategy Guides - newser.com
MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study - Fall River Herald News
Is MIRA Pharmaceuticals Inc. a candidate for recovery playPortfolio Return Report & Low Risk High Win Rate Picks - newser.com
MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals - El Paso Times
What data driven models say about MIRA Pharmaceuticals Inc.’s futureWeekly Profit Analysis & Consistent Growth Equity Picks - newser.com
Can MIRA Pharmaceuticals Inc. stock sustain free cash flow growth2025 Top Gainers & Fast Gaining Stock Reports - newser.com
Using fundamentals and technicals on MIRA Pharmaceuticals Inc.Market Activity Report & Fast Moving Stock Watchlists - newser.com
Analyzing MIRA Pharmaceuticals Inc. with multi timeframe chartsJuly 2025 Short Interest & Technical Entry and Exit Tips - newser.com
MIRA Pharmaceuticals (NASDAQ:MIRA) Stock Rating Upgraded by Wall Street Zen - Defense World
MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction - The Oklahoman
Custom strategy builders for tracking MIRA Pharmaceuticals Inc.July 2025 Fed Impact & Fast Entry High Yield Stock Tips - newser.com
MIRA Pharmaceuticals Completes SKNY Acquisition - MSN
What moving averages say about MIRA Pharmaceuticals Inc.New Guidance & Free Safe Entry Trade Signal Reports - newser.com
MIRA Pharmaceuticals completes acquisition of SKNY Pharmaceuticals By Investing.com - Investing.com Nigeria
MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals - citybiz
Mira Pharmaceuticals completes acquisition of SKNY Pharmaceuticals By Investing.com - Investing.com Nigeria
MIRA Pharmaceuticals completes acquisition of SKNY Pharmaceuticals - Investing.com
Mira Pharmaceuticals completes acquisition of SKNY Pharmaceuticals - Investing.com India
30% Weight Loss: MIRA Pharma Acquires Novel Obesity Drug SKNY-1 That Also Treats Nicotine Addiction - Stock Titan
Mira Pharmaceuticals Inc Stock (MIRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mira Pharmaceuticals Inc Stock (MIRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Aminov Erez | Chief Executive Officer |
Nov 20 '24 |
Sale |
1.27 |
44,590 |
56,629 |
1,061,200 |
1.50%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):